AI Market Mood: Stock Dashboard
UCB
Fundamental
Company: United Community Banks Inc
Sector: Financial
Industry: Banks - Regional
Country: USA
Exchange: NYSE
Index: RUT
P/E: 13.20
EPS (ttm): 2.62
Insider Own: 0.73%
Shs Outstand: 120.60M
Perf Week: -5.34%
Market Cap: 4.17B
Forward P/E: 10.70
EPS next Y: 3.23
Insider Trans: -1.69%
Shs Float: 119.71M
Perf Month: 3.50%
Enterprise Value: -
PEG: -
EPS next Q: 0.69
Inst Own: 85.64%
Short Float: 3.13%
Perf Quarter: 14.70%
Income: 318.18M
P/S: 2.71
EPS this Y: 9.79%
Inst Trans: 1.60%
Short Ratio: 4.62
Perf Half Y: 9.51%
Sales: 1.54B
P/B: 1.15
EPS next Y Percentage: 8.55%
ROA: 1.17%
Short Interest: 3.75M
Perf YTD: 10.70%
Book/sh: 30.17
P/C: -
EPS next 5Y: -
ROE: 9.23%
52W High: 36.77 -6.01%
Perf Year: 3.26%
Cash/sh: -
P/FCF: 9.82
EPS past 3/5Y: 1.30% 6.49%
ROIC: 8.46%
52W Low: 22.93 50.72%
Perf 3Y: 5.08%
Dividend Est.: 1.03 (2.97%)
EV/EBITDA: -
Sales past 3/5Y: 17.74% 16.44%
Gross Margin: -
Volatility W: 2.88%
Volatility M: 2.51%
Perf 5Y: 7.20%
Dividend TTM: 0.98 (2.84%)
EV/Sales: -
EPS Y/Y TTM: 28.38%
Oper. Margin: 28.45%
ATR (14): 0.89
Perf 10Y: 104.26%
Dividend Ex-Date: Dec 15, 2025
Quick Ratio: -
Sales Y/Y TTM: 3.61%
Profit Margin: 20.66%
RSI (14): 51.76
Recom: 2.33
Dividend Gr. 3/5Y: 4.45% 6.36%
Current Ratio: 0.03
EPS Q/Q: 14.84%
SMA20: -0.77%
Beta: 0.84
Target Price: 37.40
Payout: 37.40%
Debt/Eq: 0.06
Sales Q/Q: 4.37%
SMA50: 3.89%
Rel Volume: 0.66
Prev Close: 34.54
Employees: 2979
LT Debt/Eq: 0.03
Earnings: Jan 14 BMO
SMA200: 10.87%
Avg Volume: 810.18K
Price: 34.56
IPO: Mar 18, 2002
Option/Short: Yes / Yes
EPS/Sales Surpr.: -0.60% 1.75%
Trades:
Volume: 536,152
Change: 0.06%
Technical:
Latest News:
PEGylated Protein Therapeutics Industry Research Study |Merck, Pfizer, UCB - Economica neutral
Merck Pfizer UCB Amgen AstraZeneca Biogen Roche Horizon Pharma Leadiant Biosciences
Summary: The press release from Orbis Research highlights the extensive scope of the PEGylated Protein Therapeutics market across various regions, providing insights into market dynamics, growth rates, and market segmentation.
Full article2024-07-07T09:58:26Z
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB somewhat bearish
TAK
Summary: Takeda Pharmaceuticals is the latest company to leave the Biotechnology Innovation Organization (BIO) as it opted not to renew its membership after a routine review of trade association participation. The decision was made to further refine the focus of resources and advocate for policies putting patients first. Several other pharmaceutical companies, including Pfizer, UCB, and WuXi AppTec, have also exited prominent industry trade groups in recent times.
Full article2024-04-26T11:39:50Z